Budesonide pill may shield myeloma patients from brutal transplant diarrhea

NCT ID NCT05405387

Recruiting now Symptom relief Sponsor: University of Utah Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests whether the drug budesonide can prevent severe diarrhea in multiple myeloma patients receiving a stem cell transplant. About 120 adults will take either budesonide or a placebo for two weeks starting just before their transplant. The goal is to see if the drug reduces diarrhea and other complications, making recovery smoother.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Budesonide (Entocort EC)
What this could lead to: If it works, this could give doctors a simple way to prevent severe diarrhea during stem cell transplant for multiple myeloma, making the procedure easier to tolerate.
What could go wrong: This is a small, early-phase trial (120 people) testing a drug already used for other conditions. It may not reduce diarrhea significantly, and side effects from budesonide are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell leukemia plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA PLASMA CELL LEUKEMIA

Contacts and locations

Locations

Huntsman Cancer Institute at the University of Utah
RECRUITING

Salt Lake City, Utah, 84112, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.